BioLife Solutions Inc.
Rating
Updated: Aug 27, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across ...
Latest News
11 days ago · gurufocus.com
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial be
12 days ago · businesswire.com
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFSNEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
2 months ago · zacks.com
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass EstimatesBioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a year ago.
2 months ago · prnewswire.com
BioLife Solutions Reports Second Quarter 2026 Financial ResultsTotal revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026 BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026.
2 months ago · gurufocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS) PR Newswire
2 months ago · prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating BioLife Solutions, Inc. (NASDAQ: BLFS ) related to its sale to Repligen Corporation.
2 months ago · gurufocus.com
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public ShareholdersShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders PR
2 months ago · businesswire.com
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns w.
4 months ago · gurufocus.com
BioLife Solutions Inc (BLFS) Stock Up 3.1% and Still Undervalued -- GF Score: 73/100On May 28, 2026, BioLife Solutions Inc (BLFS) shares rose 3.1% to a current price of $25.25. This movement comes amid a 52-week range that sees a high of $29.62
5 months ago · seekingalpha.com
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call TranscriptBioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BLFS